Reasons to Add McKesson Stock to Your Portfolio Right Now

McKesson Corporation (MCK) is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The optimism, led by a decent first-quarter fiscal 2025 performance and improving demand for healthcare, is expected to contribute further. However, stiff competition and weaker generic pharmaceutical pricing trends persist.In the past year, MCK’s shares have risen 25.6% compared with the industry’s growth of 3.5%. The S&P 500 has gained 28.3% in the same time frame.The renowned healthcare ...